Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-DowngradedNASDAQ:SAGE Sage Therapeutics (SAGE) Stock Forecast, Price & News $20.08 +0.32 (+1.62%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$19.47▼$20.1350-Day Range$16.75▼$36.7452-Week Range$16.51▼$59.99Volume763,229 shsAverage Volume1.54 million shsMarket Capitalization$1.20 billionP/E RatioN/ADividend YieldN/APrice Target$43.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Sage Therapeutics MarketRank™ ForecastAnalyst RatingHold2.15 Rating ScoreUpside/Downside117.0% Upside$43.57 Price TargetShort InterestBearish18.51% of Float Sold ShortDividend StrengthN/ASustainability-1.46Upright™ Environmental ScoreNews SentimentN/AInsider TradingAcquiring Shares$37,280 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($8.93) to ($6.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.46 out of 5 starsMedical Sector189th out of 965 stocksPharmaceutical Preparations Industry66th out of 450 stocks 4.1 Analyst's Opinion Consensus RatingSage Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.15, and is based on 3 buy ratings, 17 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.57, Sage Therapeutics has a forecasted upside of 117.0% from its current price of $20.08.Amount of Analyst CoverageSage Therapeutics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.51% of the float of Sage Therapeutics has been sold short.Short Interest Ratio / Days to CoverSage Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Sage Therapeutics has recently increased by 2.70%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldSage Therapeutics does not currently pay a dividend.Dividend GrowthSage Therapeutics does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSage Therapeutics has received a 57.89% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Antidepressants" and "Clinical research services for mental health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sage Therapeutics is -1.46. Previous Next 1.4 News and Social Media Coverage News SentimentSage Therapeutics has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sage Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 10 people have searched for SAGE on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Sage Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sage Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $37,280.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Sage Therapeutics is held by insiders.Percentage Held by Institutions89.68% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sage Therapeutics are expected to grow in the coming year, from ($8.93) to ($6.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sage Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sage Therapeutics is -2.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSage Therapeutics has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sage Therapeutics (NASDAQ:SAGE) StockSage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Read More SAGE Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SAGE Stock News HeadlinesSeptember 27, 2023 | benzinga.comBipolar Disorder Pipeline, Emerging Drugs, Clinical Trials, and FDA Approvals 2023 (Updated)September 25, 2023 | americanbankingnews.comSage Therapeutics, Inc. (NASDAQ:SAGE) Receives Consensus Recommendation of "Hold" from AnalystsOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.September 15, 2023 | msn.comZuranolone: FDA-Approved Postpartum Depression MedicationSeptember 13, 2023 | finance.yahoo.comSage Therapeutics reveals number of layoffs in RaleighSeptember 13, 2023 | markets.businessinsider.comOppenheimer Reaffirms Their Hold Rating on SAGE Therapeutics (SAGE)September 11, 2023 | markets.businessinsider.comScotiabank Sticks to Its Buy Rating for SAGE Therapeutics (SAGE)September 8, 2023 | msn.comB of A Securities Maintains Sage Therapeutics (SAGE) Neutral RecommendationOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 7, 2023 | msn.comMizuho Maintains Sage Therapeutics (SAGE) Neutral RecommendationSeptember 7, 2023 | msn.comRBC Capital Maintains Sage Therapeutics (SAGE) Sector Perform RecommendationSeptember 7, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Phreesia (PHR) and SAGE Therapeutics (SAGE)September 6, 2023 | finance.yahoo.comSage Therapeutics to Present at Upcoming September Investor ConferencesSeptember 3, 2023 | msn.comSage Therapeutics fires 40% of staff after FDA rejected MDD bidSeptember 1, 2023 | msn.comSage Therapeutics to lay off about 40 percent of its workforceSeptember 1, 2023 | bizjournals.comSage Therapeutics cuts 40% of workforce following partial FDA rejectionSeptember 1, 2023 | bizjournals.comFive things: Pegasystems, Sage cuts jobs; Starry emerges; Sumner Tunnel opens, so who's on the T?August 31, 2023 | finance.yahoo.comMidday movers: Salesforce, Dollar General, Crowdstrike and moreAugust 31, 2023 | finance.yahoo.comSage cuts nearly half its staff in wake of partial FDA rejectionAugust 31, 2023 | finance.yahoo.comFDA Documents Suggest Sage's Battle In Depression Will Be Trickier Than ExpectedAugust 31, 2023 | marketwatch.comSage Therapeutics Cutting 40% of Staff in Restructuring >SAGEAugust 31, 2023 | msn.comSage Therapeutics to lay off 40% of staff as it gears up for launch of post-partum depression treatmentAugust 25, 2023 | yahoo.comZuranolone is a triumph for PPD. But its implications for women’s health research are concerningAugust 24, 2023 | finance.yahoo.comIs Sage Therapeutics Stock in Trouble After Dropping 50% in a Month?August 22, 2023 | businesswire.comSAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating Sage Therapeutics, Inc. on Behalf of Sage Stockholders and Encourages Investors to Contact the FirmAugust 19, 2023 | prnewswire.comSAGE INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the FirmAugust 14, 2023 | msn.comSage Therapeutics: Undeserving Selloff Presents A Buying OpportunitySee More Headlines Receive SAGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Company Calendar Last Earnings8/07/2023Today10/04/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SAGE CUSIPN/A CIK1597553 Webwww.sagerx.com Phone(617) 299-8380Fax617-299-8379Employees689Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.57 High Stock Price Forecast$294.00 Low Stock Price Forecast$20.00 Forecasted Upside/Downside+117.0%Consensus RatingHold Rating Score (0-4)2.15 Research Coverage20 Analysts Profitability EPS (Most Recent Fiscal Year)($9.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-532,780,000.00 Net Margins-5,704.03% Pretax Margin-5,704.03% Return on Equity-49.82% Return on Assets-45.99% Debt Debt-to-Equity RatioN/A Current Ratio10.99 Quick Ratio10.99 Sales & Book Value Annual Sales$10.37 million Price / Sales115.93 Cash FlowN/A Price / Cash FlowN/A Book Value$21.05 per share Price / Book0.95Miscellaneous Outstanding Shares59,884,000Free Float56,710,000Market Cap$1.20 billion OptionableOptionable Beta1.10 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Barry E. Greene (Age 60)Pres, CEO & Director Comp: $1.29MMs. Kimi E. Iguchi CPA (Age 61)CFO & Treasurer Comp: $665.37kMs. Anne Marie Cook Esq. (Age 61)Sr. VP, Gen. Counsel & Sec. Comp: $711.6kMr. Christopher Benecchi (Age 51)Chief Bus. Officer Comp: $703.76kDr. Laura Gault M.D.Ph.D., Chief Medical OfficerMr. Matt LasmanisChief Technology & Innovation OfficerMr. Mike QuirkChief Scientific OfficerHelen RubinsteinInvestor Relations OfficerMs. Erin E. Lanciani (Age 54)Chief People & Experience Officer Dr. Amy Schacterle Ph.D.Sr. VP of R&D Strategy and Bus. ManagementMore ExecutivesKey CompetitorsAmylyx PharmaceuticalsNASDAQ:AMLXXencorNASDAQ:XNCRRhythm PharmaceuticalsNASDAQ:RYTMTG TherapeuticsNASDAQ:TGTXSummit TherapeuticsNASDAQ:SMMTView All CompetitorsInsiders & InstitutionsAlberta Investment Management CorpSold 1,157 shares on 8/24/2023Ownership: 0.009%Wolverine Trading LLCBought 5,000 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 41,100 shares on 8/22/2023Ownership: 0.069%Teachers Retirement System of The State of KentuckyBought 952 shares on 8/21/2023Ownership: 0.127%California State Teachers Retirement SystemSold 1,540 shares on 8/21/2023Ownership: 0.108%View All Insider TransactionsView All Institutional Transactions SAGE Stock - Frequently Asked Questions Should I buy or sell Sage Therapeutics stock right now? 20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sage Therapeutics in the last twelve months. There are currently 17 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SAGE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAGE, but not buy additional shares or sell existing shares. View SAGE analyst ratings or view top-rated stocks. What is Sage Therapeutics' stock price forecast for 2023? 20 brokerages have issued 12 month target prices for Sage Therapeutics' stock. Their SAGE share price forecasts range from $20.00 to $294.00. On average, they predict the company's share price to reach $43.57 in the next year. This suggests a possible upside of 117.0% from the stock's current price. View analysts price targets for SAGE or view top-rated stocks among Wall Street analysts. How have SAGE shares performed in 2023? Sage Therapeutics' stock was trading at $38.14 on January 1st, 2023. Since then, SAGE stock has decreased by 47.4% and is now trading at $20.08. View the best growth stocks for 2023 here. When is Sage Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our SAGE earnings forecast. How were Sage Therapeutics' earnings last quarter? Sage Therapeutics, Inc. (NASDAQ:SAGE) issued its quarterly earnings results on Monday, August, 7th. The biopharmaceutical company reported ($2.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.55) by $0.13. The biopharmaceutical company had revenue of $2.47 million for the quarter, compared to analysts' expectations of $2.94 million. Sage Therapeutics had a negative trailing twelve-month return on equity of 49.82% and a negative net margin of 5,704.03%. The firm's revenue for the quarter was up 64.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.13) EPS. What ETFs hold Sage Therapeutics' stock? ETFs with the largest weight of Sage Therapeutics (NASDAQ:SAGE) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), Simplify Propel Opportunities ETF (SURI), ALPS Medical Breakthroughs ETF (SBIO) and Alpha Architect U.S. Quantitative Momentum ETF (QMOM).Invesco Dorsey Wright Healthcare Momentum ETF (PTH). What other stocks do shareholders of Sage Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sage Therapeutics investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Roku (ROKU), QUALCOMM (QCOM) and Bristol-Myers Squibb (BMY). What is Sage Therapeutics' stock symbol? Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE." How do I buy shares of Sage Therapeutics? Shares of SAGE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sage Therapeutics' stock price today? One share of SAGE stock can currently be purchased for approximately $20.08. How much money does Sage Therapeutics make? Sage Therapeutics (NASDAQ:SAGE) has a market capitalization of $1.20 billion and generates $10.37 million in revenue each year. The biopharmaceutical company earns $-532,780,000.00 in net income (profit) each year or ($9.92) on an earnings per share basis. How many employees does Sage Therapeutics have? The company employs 689 workers across the globe. How can I contact Sage Therapeutics? Sage Therapeutics' mailing address is 215 FIRST STREET, CAMBRIDGE MA, 02142. The official website for the company is www.sagerx.com. The biopharmaceutical company can be reached via phone at (617) 299-8380, via email at ir@sagerx.com, or via fax at 617-299-8379. This page (NASDAQ:SAGE) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.